FDA, Industry Reach Agreement On Major Portions Of Generic User Fee Program
This article was originally published in The Pink Sheet Daily
Executive Summary
Pending agreement includes a one-time fee for ANDA applications in the backlog.
You may also be interested in...
GDUFA Facility Fees Should Be Waived Until First ANDA Approved, Petition Argues
Bangladesh-based Square Pharmaceuticals says the fees are burdensome for first-time filers, given long approval times, but the firm’s citizen petition strategy may further delay approval of its ANDA.
Generic User Fee Waivers Created In Draft House Bill, Breaking FDA-Industry Agreement
FDA says it likely will oppose the provision because it would create more administrative complexity and increase fees paid by individual firms, but many provider and professional associations think waivers could help prevent and alleviate drug shortages.
GPhA's New CEO Ralph Neas Brings Health Reform Advocacy Experience
When Ralph Neas joins the Generic Pharmaceutical Association as CEO on Sept. 12 he will face many of the same challenges he’s had as CEO of the National Coalition on Health Care: energizing reform-minded partners to advocate for legislative and policy changes.